Page 22 - 10 Most Trusted Diagnostic Companies in India 2022

COVER STORY
• Similarly, when it comes to
popping a pill in your mouth it
involves a lot of queries, a lot of
questions, a lot of compliances and
all these cost money. from regula-
tory compliance to developments
and Innovation, at every step, you’re
talking about money. In a nutshell,
a lot of Investments are required in
this industry and in 2020, MKPPL
got a massive investment from
InvAscent, a.k.a India Lifesciences
based on our industrial innovations.
Everyone was aware that 2020 was
the peak year of covid-19 and that
was the period where investment
stopped world across. MKPPL was
among the very few companies
that got massive investments at
that time. InvAscent invested in our
potential and capabilities and the
product pipeline that will take us to
the next level. What they came in
for is what is happening at MKPPL.
• Our Transdermal oil is going in a
very big way.
• We also have our Nano mist or the
soft mist of budesonide which by
itself is a specialized product. If you
are giving a normal product vs. our
product, you’re giving 1/20th of the
dosage and the product deposits
itself very evenly on the alveoli.
|22 thecorporatereview.com | India | Vol. 3 | Issue 3 | March 2022
So this has become an extremely GROWTH PATH Our growth path is very well laid out
significant product for MKPPL for MKPPL, in these years, has moved and I think you will hear a lot more
COPD treatment. COPD it’s a life- from being a formulation interme- about MKPPL in the near future I
time disease and if you are going
to continue giving High dosages, diate to finish formulation manu- hope it’s all going to be good news.
it is going to be tough for the facturers which will lead us further. We expect to be number one in
We are not only looking at making this Niche pharmaceutical range.
concerned individual so we require finished dosage forms of the regular We look forward to being a good
a lower dosage for better treat- drugs available in the marketplace,
ment. We are going ahead with but also making finish formulations innovative company. Dreams are
registering our product in India. of innovative products and hence many, the pathways are long and
there is no time to sleep because
• Next, we have an ophthal- entering into a new niche. This we are in the most interesting
mology product to treat glau- area is what will position MKPPL
coma. The majority of OTC glau- from being a small small-sized and the most exciting part of
coma ophthalmic drugs fall more company to a Mid-Cap company our business and I think we are
out of the eye than stay in the eye. and further a Blue-chip company. going to grow the right way.
The human eye has a lipophilic
layer that protects the cornea
from any foreign object going into
the eye, hence throwing out the
drugs as well. So when you reduce
the particle size of the drug,
you are ensuring better absorp-
tion of the drug into the cornea
and thereby reducing glaucoma.
• We have utilized our technology
advancements even in Oncology
and regular dosage drugs.
“We can say that Innovation
flows in our DNA.”
|23